ASCO Breast Cancer Guidelines Again Favor of Sentinel Node Biopsy, But Differences in Practice Exist

ASCO Breast Cancer Guidelines Again Favor of Sentinel Node Biopsy, But Differences in Practice Exist
The American Society of Clinical Oncology (ASCO) recently updated its guidelines for early stage breast cancer treatment, reaffirming a 2014 recommendation of a "less-is-more" approach that favors a sentinel lymph node biopsy for evaluating and treating patients who may have malignant disease. But a researcher with a key role in these guidelines reports that many surgeons in the U.S. are still routinely performing full lymph node dissections on patients. "The new guidelines, first established in 2014, seem to have been embraced within academic centers and larger hospitals and cancer centers, but compliance is still quite variable elsewhere," Gary Lyman, a  breast cancer oncologist at the Fred Hutchinson Cancer Research Center in Seattle, Washington, said in a press release. Lyman, co-director of the Hutchinson Institute for Cancer Outcomes Research (HICOR), is first author of the recommendations, published this  month in the ASCO Journal of Clinical Oncology. The guidelines reaffirm the more conservative approach of sentinel node biopsy for evaluating breast cancer patients to stage their cancer, to de
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.